Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients

[1]  J. Douketis,et al.  Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill , 2019, Thrombosis Journal.

[2]  B. Rochwerg,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. , 2018, Blood advances.

[3]  M. Refaai,et al.  The Clinical Significance of Fibrin Monomers , 2018, Thrombosis and Haemostasis.

[4]  J. Gris,et al.  Benefit of Risk Score-Guided Prophylaxis in Pregnant Women at Risk of Thrombotic Events: A Controlled Before-and-After Implementation Study , 2018, Thrombosis and Haemostasis.

[5]  Irene Gutiérrez García,et al.  D-dimer during pregnancy: establishing trimester-specific reference intervals , 2018, Scandinavian journal of clinical and laboratory investigation.

[6]  J. Beyer-Westendorf,et al.  Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). , 2018, International journal of cardiology.

[7]  G. Raskob,et al.  Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. , 2018, Thrombosis research.

[8]  S. Goodacre,et al.  The DiPEP (Diagnosis of PE in Pregnancy) biomarker study: An observational cohort study augmented with additional cases to determine the diagnostic utility of biomarkers for suspected venous thromboembolism during pregnancy and puerperium , 2018, British journal of haematology.

[9]  Y. -. Lee,et al.  Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically Ill patients , 2017, Journal of Thrombosis and Thrombolysis.

[10]  D. Aujesky,et al.  Venous thromboembolism in the elderly: A narrative review. , 2017, Thrombosis research.

[11]  J. Benichou,et al.  Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study. , 2017, Thrombosis research.

[12]  P. Ball,et al.  Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed. , 2017, Critical reviews in oncology/hematology.

[13]  S. Kathiresan,et al.  Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor , 2017, Circulation. Cardiovascular genetics.

[14]  B. Lämmle,et al.  Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. , 2017, The American journal of medicine.

[15]  A. Mariampillai,et al.  Adherence to thromboprophylaxis guidelines in elderly patients with hospital acquired venous thromboembolism: a case control study , 2017, Journal of Thrombosis and Thrombolysis.

[16]  F. Dentali,et al.  Efficacy and safety of extended antithrombotic prophylaxis in elderly medically ill patients , 2017, European Respiratory Journal.

[17]  R. Riley,et al.  Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study , 2016, British Medical Journal.

[18]  K. Curtis,et al.  Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. , 2016, Contraception.

[19]  M. D'Alton,et al.  A comparison of recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from three major guidelines , 2016, BJOG : an international journal of obstetrics and gynaecology.

[20]  I. Greer,et al.  Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. , 2016, Blood.

[21]  B. Patel,et al.  Preventable vs Non-Preventable VTE in Hospitalized Patients , 2016 .

[22]  A. Sadlon,et al.  Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions. , 2016, Swiss medical weekly.

[23]  S. Middeldorp,et al.  Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting , 2016, Thrombosis and Haemostasis.

[24]  M. Prins,et al.  Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. , 2016, Thrombosis research.

[25]  S. Middeldorp,et al.  Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[26]  L. Lanthier,et al.  Thromboprophylaxis adherence to the ninth edition of American college of chest physicians antithrombotic guidelines in a tertiary care centre: a cross-sectional study. , 2016, Journal of evaluation in clinical practice.

[27]  P. Sandset,et al.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[28]  J. McNulty,et al.  A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women , 2016, Journal of Perinatology.

[29]  M. Rodger,et al.  Guidance for the treatment and prevention of obstetric-associated venous thromboembolism , 2016, Journal of Thrombosis and Thrombolysis.

[30]  M. Carrier,et al.  The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety , 2016, Expert opinion on drug safety.

[31]  G. Abel,et al.  Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism , 2015 .

[32]  S. Hatipoglu,et al.  A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? , 2015, Anatolian journal of cardiology.

[33]  P. Schauer,et al.  Who Should Get Extended Thromboprophylaxis After Bariatric Surgery?: A Risk Assessment Tool to Guide Indications for Post-discharge Pharmacoprophylaxis , 2015, Annals of surgery.

[34]  Z. Tong,et al.  A Survey of the Knowledge of Venous Thromboembolism Prophylaxis among the Medical Staff of Intensive Care Units in North China , 2015, PloS one.

[35]  A. Orçun,et al.  Establishing reference intervals for D-dimer to trimesters , 2015, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[36]  M. H. Ensom,et al.  Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. , 2015, The Canadian journal of hospital pharmacy.

[37]  P. McFarlane,et al.  Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. , 2015, Current oncology.

[38]  F. Dentali,et al.  Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials , 2015, Annals of medicine.

[39]  K. Kröger,et al.  Venous thromboembolism in Germany: results of the GermAn VTE registry (GATE‐registry) , 2014, International journal of clinical practice.

[40]  J. Kingdom,et al.  Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial , 2014, The Lancet.

[41]  P. Verhamme,et al.  Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants , 2014, Thrombosis Journal.

[42]  M. Monreal,et al.  Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism , 2014, Medicine.

[43]  P. Crome,et al.  The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond , 2014, Expert review of clinical pharmacology.

[44]  L. Magee,et al.  Venous thromboembolism and antithrombotic therapy in pregnancy. , 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[45]  J. Gurwitz,et al.  Venous thromboembolism in older adults: A community-based study. , 2014, The American journal of medicine.

[46]  A. Cohen,et al.  Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). , 2014, The Cochrane database of systematic reviews.

[47]  C. Kearon,et al.  Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta‐analysis , 2014, Journal of thrombosis and haemostasis : JTH.

[48]  A. Mebazaa,et al.  D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial , 2014, Journal of thrombosis and haemostasis : JTH.

[49]  A. Delluc,et al.  Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. , 2014, Thrombosis research.

[50]  O. Rutschmann,et al.  Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. , 2014, JAMA.

[51]  S. Goland,et al.  Monitoring of Anti-Xa in Pregnant Patients With Mechanical Prosthetic Valves Receiving Low-Molecular-Weight Heparin , 2014, Journal of cardiovascular pharmacology and therapeutics.

[52]  S. Goldhaber,et al.  The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. , 2014, American heart journal.

[53]  Y. Tsukahara,et al.  Use of fibrin monomer complex for screening for venous thromboembolism in the late pregnancy and post‐partum period , 2014, The journal of obstetrics and gynaecology research.

[54]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[55]  S. Gates,et al.  Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. , 2014, The Cochrane database of systematic reviews.

[56]  A. Lacy,et al.  Clinical markers of the hypercoagulable state by rotational thrombelastometry in obese patients submitted to bariatric surgery , 2014, Surgical Endoscopy.

[57]  S. Schulman.  Advantages and limitations of the new anticoagulants , 2014, Journal of internal medicine.

[58]  B. Gage,et al.  Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients , 2013, Thrombosis and Haemostasis.

[59]  R. Yusen,et al.  Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients , 2013, Thrombosis and Haemostasis.

[60]  P. Felicíssimo,et al.  Venous thromboprophylaxis duration and adherence to international guidelines in patients undergoing major orthopaedic surgery: results of the international, longitudinal, observational DEIMOS registry. , 2013, Thrombosis research.

[61]  R. Hull,et al.  Venous Thromboembolism in Elderly High-Risk Medical Patients , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[62]  P Prandoni,et al.  Prevention and treatment of venous thromboembolism--International Consensus Statement. , 2013, International angiology : a journal of the International Union of Angiology.

[63]  B. Lämmle,et al.  Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism , 2013, Journal of thrombosis and haemostasis : JTH.

[64]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[65]  W. Hooper,et al.  The effects of obesity on venous thromboembolism: A review. , 2012, Open journal of preventive medicine.

[66]  R. Pendleton,et al.  Prospective comparison of three enoxaparin dosing regimens to achieve target anti‐factor Xa levels in hospitalized, medically ill patients with extreme obesity , 2012, American journal of hematology.

[67]  E. Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[68]  D. Cook,et al.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[69]  P. Prandoni,et al.  Clinical characteristics of italian patients with venous thromboembolism enrolled in the RIETE Registry , 2011 .

[70]  F. Rosendaal,et al.  Venous thrombosis in the elderly: incidence, risk factors and risk groups , 2010, Journal of thrombosis and haemostasis : JTH.

[71]  Joseph M. Galante,et al.  PL-202: Bariatric surgery in the balance: A paradigm shift in general surgery , 2010 .

[72]  L. Pal,et al.  Predictors of chronic disease at midlife and beyond--the health risks of obesity. , 2010, Maturitas.

[73]  L. Ferrucci,et al.  Correlates of D-dimer in older persons , 2010, Aging clinical and experimental research.

[74]  F. Dentali,et al.  Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). , 2009, Thrombosis research.

[75]  D. Mottier,et al.  Primary prevention of venous thromboembolism in elderly medical patients , 2008, Clinical interventions in aging.

[76]  M. Spannagl,et al.  Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women , 2007, Thrombosis and Haemostasis.

[77]  C. Esmon,et al.  Venous thrombosis in the elderly: more questions than answers. , 2007, Blood.

[78]  R. White.  The Epidemiology of Venous Thromboembolism , 2003, Circulation.

[79]  S. Mouly,et al.  Thromboprophylaxis in Medical Patients: Focus on France , 2002, Seminars in thrombosis and hemostasis.

[80]  B. Boneu,et al.  How and when to monitor a patient treated with low molecular weight heparin. , 2001, Seminars in thrombosis and hemostasis.

[81]  R. Silver,et al.  Heparin-induced thrombocytopenia is rare in pregnancy. , 2001, American journal of obstetrics and gynecology.

[82]  M. Samama,et al.  Contemporary laboratory monitoring of low molecular weight heparins. , 1995, Clinics in laboratory medicine.

[83]  Hany R. Guirguis,et al.  Thromboprophylaxis for Hospitalized Medical Patients , 2019 .

[84]  R. Arya,et al.  Impact on thromboprophylaxis rates of implementing Royal College of Obstetricians and Gynaecologists’ guidance for reducing the risk of ante and postnatal venous thromboembolism , 2017 .

[85]  E. Halvorson,et al.  Association of Obesity and Pediatric Venous Thromboembolism. , 2016, Hospital pediatrics.

[86]  P. McFarlane,et al.  Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. , 2015, Current oncology.

[87]  S. Laporte,et al.  Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women. , 2008, Thrombosis research.

[88]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[89]  G. Raskob,et al.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies , 2013, Thrombosis Journal.